To see current research studies related to rheumatology being conducted at Nationwide Children's Hospital, search the options below.
ACV01 Clinical Trial Investigating Vaccine Booster Response in Autoimmune Disease Patients
Many people with autoimmune disease are at risk for COVID-19 infection because of the medications they take. These individuals are now eligible to receive an additional dose of an mRNA COVID-19 vaccine.
However, there are large gaps in our understanding of who will benefit from an additional dose of vaccine and how to make it work better.
The Autoimmunity Centers of Excellence, sponsored by the National Institute of Allergy and Infectious Diseases, has opened a clinical trial called ACV01 to address many of these questions.
As new information is learned, the ACV01 study will change to answer questions about more autoimmune diseases, other medications, and pediatric populations.
Help us learn as much as we can about the best way to help people with autoimmune patients protect themselves against COVID-19.
- DISEASE INVOLVEMENT: The trial is enrolling people with lupus, rheumatoid arthritis, scleroderma, multiple sclerosis, and pemphigus.
- VACCINE RESPONSE: Participants must have had a low antibody response to their initial vaccine regimen to participate.
- REQUIRED MEDICATIONS: Participants must be taking mycophenolate, methotrexate, or a B-cell depleting therapy like rituximab or ofatumumab.
- HELP US CLOSE THE GAPS: To find out more visit our ACV01 public website.
Visit AutoimmuneCovidBooster.org to learn more.